Chemotherapy for androgen-independent prostate cancerPETRYLAK, Daniel P.World journal of urology (Print). 2005, Vol 23, Num 1, pp 10-13, issn 0724-4983, 4 p.Article

Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapyJUN DU; QING YANG; CHEN, Xu-Sheng et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 5, pp 1055-1061, issn 0344-5704, 7 p.Article

Hedgehog Signalling in Androgen Independent Prostate Cancer. CommentarySHAW, Greg; PRICE, Anna M; KTORI, Elena et al.European urology. 2008, Vol 54, Num 6, pp 1333-1343, issn 0302-2838, 11 p.Article

Emerging Treatment Options for Patients With Castration-Resistant Prostate CancerGEORGE, Daniel; MOUL, Judd W.The Prostate. 2012, Vol 72, Num 3, pp 338-349, issn 0270-4137, 12 p.Article

Longitudinal Analysis of Androgen Deprivation of Prostate Cancer Cells Identifies Pathways to Androgen IndependenceD'ANTONIO, Jason M; CHANGQING MA; MONZON, Federico A et al.The Prostate. 2008, Vol 68, Num 7, pp 698-714, issn 0270-4137, 17 p.Article

Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cellsGONG, J; ZHU, J; GOODMAN, O. B et al.Oncogene (Basingstoke). 2006, Vol 25, Num 14, pp 2011-2021, issn 0950-9232, 11 p.Article

Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancerNISHIYAMA, Tsutomu; SUZUKI, Kazuya; YAMANA, Kazutoshi et al.Expert review of anticancer therapy. 2006, Vol 6, Num 2, pp 259-268, issn 1473-7140, 10 p.Article

Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androqen-independent prostate cancerSELLA, Avishay; STERNBERG, Cora N; SKONECZNA, Iwona et al.BJU international (Papier). 2008, Vol 102, Num 11, pp 1607-1609, issn 1464-4096, 3 p.Article

In vitro and invivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinomaFESTUCCIA, Claudio; GRAVINA, Giovanni Luca; MUZI, Paola et al.The Prostate. 2007, Vol 67, Num 12, pp 1255-1264, issn 0270-4137, 10 p.Article

Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancerRIGAS, A. C; ROBSON, C. N; CURTIN, N. J et al.Oncogene (Basingstoke). 2007, Vol 26, Num 55, pp 7611-7619, issn 0950-9232, 9 p.Article

Current Applications for Prostate-Specific Antigen Doubling Time. CommentariesRAMIREZ, Michelle L; NELSON, Eric C; DEVERE WHITE, Ralph W et al.European urology. 2008, Vol 54, Num 2, pp 291-302, issn 0302-2838, 12 p.Article

Prostate cancer and markers of bone metabolism : diagnostic, prognostic, and therapeutic implicationsNELSON, Eric C; EVANS, Christopher P; PAN, Chong-Xian et al.World journal of urology (Print). 2007, Vol 25, Num 4, pp 393-399, issn 0724-4983, 7 p.Article

Progression after docetaxel-based chemotherapy in androgen-independent prostate cancerSELLA, Avishay; STERNBERG, Cora; KOVEL, Svetlana et al.BJU international (Papier). 2007, Vol 100, Num 3, pp 533-535, issn 1464-4096, 3 p.Article

Active Sonic Hedgehog Signaling Between Androgen Independent Human Prostate Cancer Cells and Normal/Benign but Not Cancer-Associated Prostate Stromal CellsSHIGEMURA, Katsumi; HUANG, Wen-Chin; XIANGYAN LI et al.The Prostate. 2011, Vol 71, Num 16, pp 1711-1722, issn 0270-4137, 12 p.Article

The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer : experimental dataLO NIGRO, Cristiana; MAFFI, Monica; FISCHEL, Jean Louis et al.BJU international (Papier). 2008, Vol 102, Num 5, pp 622-627, issn 1464-4096, 6 p.Article

Dose-Dependent Growth Inhibition InVivo of PC-3 Prostate Cancer With a Reduction in Tumoral Growth Factors AfterTherapy With GHRH Antagonist MZ-J-7-138HEINRICH, Elmar; SCHALLY, Andrew V; BUCHHOLZ, Stefan et al.The Prostate. 2008, Vol 68, Num 16, pp 1763-1772, issn 0270-4137, 10 p.Article

An androgen-independent androgen receptor function protects from inositol HexakisphosphateToxicity in the PC3/PC3(AR) prostate cancer cell linesDIALLO, Jean-Simon; PEANT, Benjamin; LESSARD, Laurent et al.The Prostate. 2006, Vol 66, Num 12, pp 1245-1256, issn 0270-4137, 12 p.Article

Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-lndependent prostate cancerNAKABAYASHI, Mari; WANLING XIE; REGAN, Meredith M et al.Cancer. 2006, Vol 107, Num 5, pp 975-981, issn 0008-543X, 7 p.Article

Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancerBORDEN, Lester S; CLARK, Peter E; LOVATO, James et al.Cancer. 2006, Vol 107, Num 5, pp 1093-1100, issn 0008-543X, 8 p.Article

Conversion of Prostate Cancer from Hormone Independency to Dependency Due to AMACR Inhibition: Involvement of Increased AR Expression and Decreased IGF1 ExpressionTAKAHARA, Kiyoshi; AZUMA, Haruhito; KATSUOKA, Yoji et al.Anticancer research. 2009, Vol 29, Num 7, pp 2497-2505, issn 0250-7005, 9 p.Article

Antagonists of Growth Hormone Releasing Hormone (GHRH) and of Bombesin/Gastrin Releasing Peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC -3 and DU-145 human androgen-lndependent prostate cancersSTANGELBERGER, Anton; SCHALLY, Andrew V; VARGA, Jozsef L et al.The Prostate. 2005, Vol 64, Num 3, pp 303-315, issn 0270-4137, 13 p.Article